Honey Bee Hymenoptera Venom Venomil Diagnostic Kit
NDC Package 65044-9986-1

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings

Package Information

Honey Bee Hymenoptera Venom Venomil Diagnostic kits is insect stings may induce a wide range of allergic symptoms in sensitive patients. This formulation utilizes a kit delivery system. Marketed by Jubilant Hollisterstier Llc, this product is identified by NDC 65044-9986 and is authorized under FDA application BLA103882.

Identification & Billing

NDC Package Code
65044-9986-1
Package Description
1 KIT in 1 TRAY * 1.2 mL in 1 VIAL (65044-9980-2)
Product Code
11-Digit Billing Format
65044998601
RxNorm Crosswalk
  • RxCUI: 1294639 - common paper wasp venom protein 0.025 MG/mL / metricus paper wasp venom protein 0.025 MG/mL / northern paper wasp venom protein 0.025 MG/mL / red paper wasp venom protein 0.025 MG/mL Injectable Solution
  • RxCUI: 1294639 - common paper wasp venom protein 0.025 MG/ML / metricus paper wasp venom protein 0.025 MG/ML / northern paper wasp venom protein 0.025 MG/ML / red paper wasp venom protein 0.025 MG/ML Injectable Solution
  • RxCUI: 1294639 - Polistes exclamans venom protein 0.025 MG/ML / Polistes metricus venom protein 0.025 MG/ML / Polistes fuscatus venom protein 25 MCG / Polistes annularis venom protein 0.025 MG/ML Powder for Injectable Solution
  • RxCUI: 1294639 - Polistes exclamans venom protein 25 MCG / Polistes metricus venom protein 25 MCG / Polistes fuscatus venom protein 25 MCG / Polistes annularis venom protein 25 MCG per 1 ML Powder for Injectable Solution
  • RxCUI: 1297542 - bald-faced hornet venom protein 0.1 MG/mL / common wasp venom protein 0.02 MG/mL / eastern yellow jacket venom protein 0.02 MG/mL / German wasp venom protein 0.02 MG/mL / southern yellow jacket venom protein 0.02 MG/mL / western yellow jacket venom protein 0.02 MG/mL / yellow hornet venom protein 0.1 MG/mL Injectable Solution

Clinical Specifications

Proprietary Name
Honey Bee Hymenoptera Venom Venomil Diagnostic
Non-Proprietary Name
Honey Bee Hymenoptera Venom Venomil Diagnostic
Dosage Form
Kit - A packaged collection of related material.
Administration Route
  • Intradermal - Administration within the dermis.
  • Percutaneous - Administration through the skin.
Usage Information
Insect stings may induce a wide range of allergic symptoms in sensitive patients. A normal sting response is initial burning or stinging pain that may be intense and last several minutes to an hour or more. There is usually some local swelling coming on immediately and persisting for several days. The location of the sting has considerable influence on the intensity of the pain and extent of swelling. Stings on the fingers or feet produce much pain, but less swelling; whereas a sting on the head or face produces extensive swelling with variable pain.Local reactions coming on rapidly and larger than the usual local reaction, particularly if the swelling spans both adjacent joints on the extremities, can indicate hypersensitivity. Systemic symptoms come on shortly after the sting, often within seconds to minutes. Symptoms may range from generalized flushing, itching, redness, diffuse swelling of the skin or urticarial wheals, abdominal cramps, nausea, vomiting, or incontinence of urine or stool, to faintness, blurring or loss of vision, unconsciousness, seizures, respiratory or cardiac arrest, or death. Later reactions may consist of fever, achiness, malaise, joint swelling, urticaria or other signs of vascular damage typical of serum sickness, a Type III reaction. Typical delayed Type IV reactions may also occur.(6) Rarely, other types of severe reactions to insect stings have been reported.(6)These include serum sickness, hematologic abnormalities, and neurological disorders commencing some time after a sting, and not associated with anaphylactoid reactions. These patients are not candidates for immunotherapy using insect venoms. (1) DiagnosisSkin testing with insect venoms is useful to demonstrate the presence of IgE antibodies which account for the patient's symptoms.(3)Patients are seldom able to identify the insect which stung them, so skin testing is used to determine the insect culprit. Dilutions of these venom products will help judge the sensitivity of the patient and whether the patient should be treated.(7)It is not absolutely known what levels (micrograms) of venom, that elicit positive skin tests, are diagnostic of clinical sensitivity. However, patients with a history of reactions (any of three types: generalized urticaria or angioedema; respiratory difficulty due either to laryngeal edema or to bronchospasm; or vascular collapse, with or without loss of consciousness) to previous stings and a positive skin test to a venom intradermal injection of approximately 1 µg/mL had about a 60% chance of reacting again when stung by the same insect. These patients should receive venom immunotherapy.(3)Patients with a history of reaction (any of the three reaction types described above) to previous stings, but who did not demonstrate a positive skin test reaction to venom, were considered in a previous study not to be clinically sensitive, and were not treated.(3) We cannot recommend treatment for such patients.Another study demonstrated false positive reactions when skin testing with venom concentrations of 10 µg/mL and 100 µg/mL was carried out.(8) Thus there can be a nonspecific skin test reaction potentially due to the pharmacological action of the venom at higher concentrations.The best statement that can be made, at present, is that patients with significant positive history (reactions of the three types described above) following an insect sting, and who do react with a positive skin test to a venom concentration of 1 µg/mL or less, are recommended for treatment. Patients who have the history described above, but who do not react to a 1 µg/mL intradermal venom skin test, cannot be recommended for treatment. At present, the data does not exist, to determine whether a patient who might react to a higher concentration, e.g., 2-10 µg/mL, is at risk from a subsequent sting or not. Since it is not known if sting-sensitive patients who subsequently lose their IgE anti-venom antibody can be resensitized by further stings, it is advisable to retest these patients after any subsequent stings.(3) However, since the level of venom-specific IgE may fall to low levels briefly after a sting, patients should not be re-tested until 2 to 4 weeks after any sting.(2) TreatmentImmunotherapy is indicated for those patients diagnosed as sensitive (see Diagnosis above) and is accomplished by using graduated dilutions of the appropriate insect venom or venoms to control the severity of the patient's symptoms from subsequent stings.Increasing doses of venom are given at intervals, dependent on the patient's ability to tolerate the venoms, until a maintenance dosage (100 µg per venom is recommended - 300 µg in the case of the Mixed Vespid venom protein) is reached and maintained.Venom sensitivity differs for individual patients, thus it is not possible to provide a dosage schedule that is universally suited to all patients. The dosage schedule shown under DOSAGE AND ADMINISTRATION is a summary of the schedule used in clinical trials of our product and found suitable for the majority of patients.In highly sensitive patients, the physician may be required to use a modified dose schedule, based on the patient's sensitivity to and tolerance of the injections. Lower initial doses and smaller dosage increments than shown under DOSAGE AND ADMINISTRATION may be necessary.

Regulatory & Marketing

Labeler Name
Jubilant Hollisterstier Llc
Product Type
Standardized Allergenic
FDA Application #
BLA103882
Marketing Category
BLA - A product marketed under an approved Biologic License Application.
Start Marketing Date
02-22-1982
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 65044-9986-1 identifies a specific commercial package of 1 kit in 1 tray * 1.2 ml in 1 vial (65044-9980-2) of Honey Bee Hymenoptera Venom Venomil Diagnostic, a standardized allergenic label labeled by Jubilant Hollisterstier Llc. This kit is formulated for intradermal; percutaneous use and contains as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Jubilant Hollisterstier Llc on February 22, 1982. The current certification is valid through December 31, 2026.

How is this Jubilant Hollisterstier Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 65044998601. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
65044-9986-1
11-Digit CMS (5-4-2)
65044-9986-01

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.